• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Ibrutinib and antimicrobial therapy in a heavily pretreated patient with chronic lymphocytic leukaemia and disseminated cutaneous non-tuberculous mycobacterial infection: successful surgery-free approach.

作者信息

Maddy Laura E, O'Brien Daniel P, Campbell Philip J

机构信息

Haematology Department, University Hospital Geelong, Geelong, Victoria, Australia.

Department of Medicine and Infectious Diseases, Royal Melbourne Hospital, The University of Melbourne, Melbourne, Victoria, Australia.

出版信息

Intern Med J. 2018 Apr;48(4):477-479. doi: 10.1111/imj.13756.

DOI:10.1111/imj.13756
PMID:29623996
Abstract
摘要

相似文献

1
Ibrutinib and antimicrobial therapy in a heavily pretreated patient with chronic lymphocytic leukaemia and disseminated cutaneous non-tuberculous mycobacterial infection: successful surgery-free approach.
Intern Med J. 2018 Apr;48(4):477-479. doi: 10.1111/imj.13756.
2
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.伊布替尼联合奥滨尤妥珠单抗与苯丁酸氮芥联合奥滨尤妥珠单抗一线治疗慢性淋巴细胞白血病（ILLUMINATE）：一项多中心、随机、开放标签、III 期临床试验。
Lancet Oncol. 2019 Jan;20(1):43-56. doi: 10.1016/S1470-2045(18)30788-5. Epub 2018 Dec 3.
3
BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome.BCR激酶抑制剂，idelalisib和伊布替尼，在Richter综合征中具有活性且有效。
Br J Haematol. 2019 Apr;185(1):193-197. doi: 10.1111/bjh.15440. Epub 2018 Jul 5.
4
Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial.奥妥珠单抗联合伊布替尼诱导治疗，随后采用微小残留病驱动策略治疗慢性淋巴细胞白血病患者（ICLL07 FILO）：一项单臂、多中心、2期试验。
Lancet Haematol. 2019 Sep;6(9):e470-e479. doi: 10.1016/S2352-3026(19)30113-9. Epub 2019 Jul 16.
5
Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia.依鲁替尼是治疗慢性淋巴细胞白血病自身免疫性溶血性贫血的有效药物。
Br J Haematol. 2015 Sep;170(5):734-6. doi: 10.1111/bjh.13328. Epub 2015 Feb 25.
6
Invasive aspergillosis with pulmonary and central nervous system involvement during ibrutinib therapy for relapsed chronic lymphocytic leukaemia: case report.依鲁替尼治疗复发慢性淋巴细胞白血病期间并发累及肺和中枢神经系统的侵袭性曲霉病：病例报告
Clin Microbiol Infect. 2018 Jul;24(7):785-786. doi: 10.1016/j.cmi.2018.01.028. Epub 2018 Feb 7.
7
Splenic rupture following temporary cessation of ibrutinib.伊布替尼暂时停药后发生脾破裂。
Br J Haematol. 2017 Nov;179(3):361. doi: 10.1111/bjh.14845. Epub 2017 Jul 24.
8
Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.一线伊布替尼治疗老年慢性淋巴细胞白血病患者的持续疗效和详细临床随访：RESONATE-2 扩展阶段 3 的结果。
Haematologica. 2018 Sep;103(9):1502-1510. doi: 10.3324/haematol.2018.192328. Epub 2018 Jun 7.
9
The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia.HELIOS试验方案：一项关于伊布替尼联合苯达莫司汀和利妥昔单抗治疗复发/难治性慢性淋巴细胞白血病的III期研究。
Future Oncol. 2015;11(1):51-9. doi: 10.2217/fon.14.119.
10
HBV reactivation in CLL patients with occult HBV infection treated with ibrutinib without viral prophylaxis.在未进行病毒预防的情况下接受依鲁替尼治疗的隐匿性HBV感染的CLL患者中HBV再激活。
Leuk Lymphoma. 2019 May;60(5):1340-1342. doi: 10.1080/10428194.2018.1523401. Epub 2019 Feb 7.